Managing vesicant extravasations

Oncologist

Volumn 13, Issue 3, 2008, Pages 284-288

  Schulmeister, Lisa ^a  

^a NONE   (United States)

Author keywords

Tissue necrosis; Vesicant extravasation; Vesicant extravasation treatment

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; CHLORMETHINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; HYALURONIDASE; HYLENEX; ICE; IDARUBICIN; NAVELBINE; PACLITAXEL; RAZOXANE; SODIUM THIOSULFATE; TOTECT; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; BLISTER; BODY SURFACE; BONE MARROW SUPPRESSION; CHEMOTHERAPY; CHILL; COLD TREATMENT; CREATININE CLEARANCE; DEBRIDEMENT; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG MECHANISM; EXTRAVASATION; FEVER; HEAT TREATMENT; HUMAN; IMPLANT; INFORMATION; INJECTION SITE BURNING; NAUSEA AND VOMITING; PATIENT MONITORING; PERMEABILITY; PRIORITY JOURNAL; REVIEW; RISK; SAFETY; SIDE EFFECT; SKIN EXFOLIATION; SKIN GRAFT; STOMATITIS; SYSTEMIC THERAPY; TISSUE NECROSIS; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; IRRITANTS; LIABILITY, LEGAL; NECROSIS; NEOPLASMS; RISK FACTORS;

EID: 43549119545     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0191     Document Type: Review

References (16)

1. Langstein HN, Duman H, Seelig D et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002;49:369-374.
2. Barlock AL, Howser DM, Hubbard SM. Nursing management of adriamycin extravasation. Am J Nurs 1979;79:94-96.
3. Bozkurt AK, Uzel B, Akman C et al. Intrathoracic extravasation of antineoplastic agents: Case reports and systematic review. Am J Clin Oncol 2003;26:121-123.
4. Schulmeister L, Camp-Sorrell D. Extravasations from implanted ports. Oncol Nurs Forum 2000;27:531-540.
5. Goossens S, Jerome M, Stas M. Occlusion in totally implantable vascular access devices: What is its incidence and what actions do nurses take to restore patency? 2005. Available at http://www.uzleuven.be/UZRoot/files/webeditor/ poster_katherzorg.pdf. Accessed September 26, 2007.
6. Ponec D, Irwin D, Haire WD et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial - the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001;12:951-955.
7. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hematooncological therapies. Ann Oncol 2004;15:858-862.
8. Polovich M, White JM, Kelleher LO. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice, Second Edition. Pittsburgh, PA: Oncology Nursing Society, 2005:82-83.
9. Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: Prevention and treatment. Semin Oncol 2006;33:139-143.
10. Schulmeister L. Extravasation management. Semin Oncol Nurs 2007;23:184-190.
11. U.S. Food and Drug Administration. Drug Details (Totect). Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed March 14, 2008.
12. Schulmeister L. Totect™: A new agent for treating anthracycline extravasation. Clin J Oncol Nurs 2007;11:387-395.
13. Mouridsen HT, Langer SW, Buter J et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): Results from two prospective clinical multicentre studies. Ann Oncol 2007;18:546-550.
14. Totect™ (dexrazoxane for injection) [package insert]. Rockaway NJ: TopoTarget USA, Inc., 2007.
15. Mustargen® (mechlorethamine HCl for injection) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2002.
16. Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003;11:270-277.